Baseline Prognostic Factors and Statistic Model to Predict Early Virological Response in Telbivudine-Treated Patients With Chronic Hepatitis B

Zhou, Rui; Zhou, Yuanping; Lin, Chun; Gao, Haibing; Huang, Shuiwen; Huang, Zuxiong; Sun, Fang; Lin, Yong; Zhang, Dongqing; Lin, Qingfeng; Ao, Wen; Chen, Pan

doi:10.5812/hepatmon.15573

Cited by 4 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of these, baseline HBeAg status, HBV DNA level, and HBV genotype are the most important predictors [21, 22]. The studies included in the present meta-analysis did not report HBV genotypes.…”

Section: Discussionmentioning

confidence: 99%

The Effect of Hepatosteatosis on Response to Antiviral Treatment in Patients with Chronic Hepatitis B: A Meta-Analysis

Zhu

Yang

et al. 2017

Gastroenterology Research and Practice

View full text Add to dashboard Cite

Background. This study is to systematically analyze the effects of hepatosteatosis on the response to antiviral treatment in patients with chronic hepatitis B (CHB) and hepatosteatosis. Methods. Systematic search was performed in PubMed, Embase, Web of Science, Elsevier, and the Chinese BioMedical literature databases for relevant studies published until February 2016. Treatment outcomes were compared between patients with CHB plus concomitant hepatosteatosis and those without hepatosteatosis. Results. A total of 8 prospective cohort studies (399 patients with CHB plus hepatosteatosis and 688 patients with only CHB) were included. Biochemical and virological response at both 48 and 96 weeks were significantly lower in patients with CHB plus hepatosteatosis as compared to that in patients with only CHB. Subgroup analysis based on methods used for diagnosis of hepatosteatosis and treatment regimens showed that when hepatosteatosis was diagnosed on Doppler ultrasound and treated with nucleotide analogues, patients with CHB plus hepatosteatosis showed lower biochemical (62.7% versus 75.8%, P = 0.002) and virological response (66.2% versus 72.3%, P = 0.006) as compared to that in patients with CHB. Conclusion. Hepatosteatosis lowers the efficacy of antiviral treatment in patients with CHB, especially when hepatosteatosis was diagnosed on ultrasound findings and treated with nucleotide analogues.

show abstract

Section: Discussionmentioning

confidence: 99%

The Effect of Hepatosteatosis on Response to Antiviral Treatment in Patients with Chronic Hepatitis B: A Meta-Analysis

Zhu

Yang

et al. 2017

Gastroenterology Research and Practice

View full text Add to dashboard Cite

show abstract

“…Furthermore, HBV DNA, is the template for gene transcription and replication, correlating robustly with levels of total intracellular HBV DNA, serum HBV DNA, and HBsAg (14). Thus, HBV DNA level is the most important and most direct etiological evidence for HBV (17). However, in developing countries endemic for HBV (18), robust, cheaper, and easy-to-perform markers are essential in the management and monitoring of HBV patients (19).…”

Section: Discussionmentioning

confidence: 99%

Correlation of Quantitative Assay of HBsAg and Hepatitis B Virus DNA Levels Among Chronic HBV Patients Attending Pathologist Lancet Laboratory in Nairobi, Kenya

Mathai

Ngayo

Karanja

et al. 2017

Arch Clin Infect Dis

View full text Add to dashboard Cite

Background: Hepatitis B Virus (HBV) viral load measurements is recommended for diagnosis and monitoring of patients on treatment for Chronic Hepatitis B (CHB). However, these diagnostic techniques are molecular-based and expensive and unavailable to majority of the Kenyan population. Quantitation of hepatitis B surface antigen (HBsAg) by automated chemiluminescent microparticle immunoassay has been proposed as a surrogate marker. Objectives: This study showed the correlation between HBsAg and HBV DNA levels among patients with CHB attending a referral Laboratory in Nairobi, Kenya. Methods: One hundred and seventy-three (173) patients were enrolled while excluding Hepatitis C Virus (HCV) and Hepatitis D Virus (HDV) positive patients. Results:The mean age of the study patients was 37.2 years, 112 (64.7%) were male, and 142 (82.1%) were hepatitis B e antigen (HBeAg) negative while 31/173 (17.9%) were HBeAg positive. The mean HBV DNA level was 2.89 log10 IU/mL and 41 (23.7%) had a baseline HBV DNA level of > 2000 IU/mL. By Mann-Whitney test, HBV DNA levels differed significantly between HBeAg positive and negative patients (P = 0.001), as did HBsAg titer (P = 0.032). Unfortunately, according to the Spearman test, there was a weak correlation between HBsAg and HBV DNA levels (P = 0.024 and r = 0.171). Conclusions: Patients with HBeAg negative test results had lower levels of HBsAg and lower levels of HBV DNA. Serum quantitation of HBsAg may not replace serum HBV DNA levels among patients with CHB in Nairobi Kenya.

show abstract

“…Lamivudine (LAM) was the first NUC introduced in the clinical practice, but currently it is not recommended in the treatment of CHB due to the high rate of drug resistance, which was found to be 24% after the 1st treatment year and increases to 49% and 70% after 3 and 5 years of LAM therapy, respectively (6). Resistance occurs more frequently in subjects with high viral load and in those who failed to achieve complete HBV DNA suppression within 6 months (7,8).…”

Section: Introductionmentioning

confidence: 99%

Lamivudine today: Experience in a single Bulgarian center

Krasteva¹,

Jelev²,

Antonov³

et al. 2018

MedInform

View full text Add to dashboard Cite

Lamivudine (LAM) is not recommended in the treatment of chronic hepatitis B due to high-rate of resistance: 49% to 70% after 3rd and 5th treatment year. LAM-resistance is more frequent in cases with high viral load or lack of complete HBV-DNA suppression within 6 months. Antiviral effect of LAM is rapid and potent if HBV-DNA level is low. Subjects who are indicated for prophylactic NUC-therapy prior immunosuppression as well as cirrhotics are with relatively low viral load, but data on the LAM efficacy in such patient populations are limited. We evaluated 97 patients (56 males) with chronic HBV-infection, mean age 56.5 (±13.1) years. Of them: 54 (56%) were with liver cirrhosis; 18 (18.5%) were with hematological malignancy or carcinoma and 16 (16.5%) with systemic autoimmune diseases. The rest 9 patients were of older age or started LAM after unsuccessful IFN-therapy. Initially 88 (91%) were HBeAg-negative. Co-infections with HCV and HDV were excluded. Patients received LAM 100mg/d for at least 36 months or until development of resistance. HBV-DNA was measured on 3-month interval by real-time PCR. Test for LAM-resistant mutations was performed in case of viral breakthrough.

show abstract

Baseline Prognostic Factors and Statistic Model to Predict Early Virological Response in Telbivudine-Treated Patients With Chronic Hepatitis B

Cited by 4 publications

References 27 publications

The Effect of Hepatosteatosis on Response to Antiviral Treatment in Patients with Chronic Hepatitis B: A Meta-Analysis

The Effect of Hepatosteatosis on Response to Antiviral Treatment in Patients with Chronic Hepatitis B: A Meta-Analysis

Correlation of Quantitative Assay of HBsAg and Hepatitis B Virus DNA Levels Among Chronic HBV Patients Attending Pathologist Lancet Laboratory in Nairobi, Kenya

Lamivudine today: Experience in a single Bulgarian center

Contact Info

Product

Resources

About